PARI Pharma

Forty years of engineering inhalation therapy devices has made PARI Pharma one of the most recognised names in respiratory drug delivery. The German company designs and manufactures nebulisers, inhalation systems, and associated drug delivery platforms used by patients and clinicians worldwide, with a particular focus on conditions such as cystic fibrosis, asthma, and chronic obstructive pulmonary disease.

Headquartered in Starnberg, Bavaria, PARI operates as a privately held group with subsidiaries and distribution partners across Europe, North America, and beyond. Its product portfolio spans handheld and compressor-driven nebulisers, mesh nebuliser technology, and purpose-built inhalation devices designed for specific therapeutic applications. The company's eFlow technology platform, which uses vibrating mesh to produce a precisely controlled aerosol, has become widely adopted in clinical trials and commercial inhaled therapies.

PARI maintains a dedicated pharmaceutical division, PARI Pharma GmbH, which partners with drug developers to optimise formulations for inhalation delivery and to supply the device component required for regulatory submissions. This positions the company at the intersection of medical devices and pharmaceutical development, supporting partners through preclinical, clinical, and commercial stages.

The group's long-standing specialism in aerosol science and device engineering gives it a distinctive role in the development of inhaled biologics and new molecular entities that require non-standard delivery mechanisms. Further information is available at pari.com.